利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.028 秒)

    STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY
    1.
    发明申请
    STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY 有权
    作为FLT3受体酪氨酸激酶活性的抑制剂的酪氨酸衍生物

    公开(公告)号：US20120252785A1

    公开(公告)日：2012-10-04

    申请号：US13524340

    申请日：2012-06-15

    申请人： James Douglas GRIFFIN ,  Paul William MANLEY

    发明人： James Douglas GRIFFIN ,  Paul William MANLEY

    IPC分类号： A61K31/553 ,  A61P35/00

    CPC分类号： A61K31/407 ,  A61K31/535 ,  A61K31/55 ,  A61K31/553

    摘要： The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

    摘要翻译： 本发明涉及星形孢菌素衍生物在制备用于治疗涉及失调的FLT3受体酪氨酸激酶活性的疾病的药物中的用途，特别是用于治疗和/或预防性治疗白血病和骨髓增生异常综合征，以及治疗方法 涉及失调的FLT3受体酪氨酸激酶活性的疾病。

    Phthalazine Derivatives with Angiogenesis Inhibiting Activity
    4.
    发明申请
    Phthalazine Derivatives with Angiogenesis Inhibiting Activity 失效
    具有血管发生抑制活性的酞嗪衍生物

    公开(公告)号：US20110130399A1

    公开(公告)日：2011-06-02

    申请号：US12953837

    申请日：2010-11-24

    申请人： Guido BOLD ,  Paul William MANLEY

    发明人： Guido BOLD ,  Paul William MANLEY

    IPC分类号： A61K31/5377 ,  C07D401/06 ,  A61K31/502 ,  C07D401/14 ,  C07D413/14 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00

    CPC分类号： C07D401/06 ,  C07D405/12 ,  C07D409/12

    摘要： The invention relates to new phthalazine derivatives of formula I, and to processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof alone or in combination with one or more other pharmaceutically active compounds for the treatment especially of a disease that responds to the inhibition of especially the vascular endothelial growth factor receptor kinase, preferably the treatment of a proliferative disease, or the treatment of inflammatory rheumatic or rheumatoid arthritis and/or pain; and the use of such a compound alone or in combination with one or more other pharmaceutically active compounds for the manufacture of a pharmaceutical preparation for the treatment of said diseases in an animal.

    摘要翻译： 本发明涉及式I的新的酞嗪衍生物及其制备方法，其在治疗人或动物体的方法中的应用，其单独使用或与一种或多种其它药物活性化合物的组合 特别是治疗特别是对特别是血管内皮生长因子受体激酶的抑制，优选治疗增殖性疾病或治疗炎性风湿性或类风湿性关节炎和/或疼痛的疾病的治疗; 以及这种化合物单独使用或与一种或多种其它药学活性化合物组合用于制备用于治疗动物中所述疾病的药物制剂。

    INHIBITORS OF TYROSINE KINASES
    6.
    发明申请
    INHIBITORS OF TYROSINE KINASES 审中-公开
    TYROSINE KINASES的抑制剂

    公开(公告)号：US20110218187A1

    公开(公告)日：2011-09-08

    申请号：US13106582

    申请日：2011-05-12

    申请人： Werner BREITENSTEIN ,  Pascal FURET ,  Sandra JACOB ,  Paul William MANLEY

    发明人： Werner BREITENSTEIN ,  Pascal FURET ,  Sandra JACOB ,  Paul William MANLEY

    IPC分类号： A61K31/55 ,  C07D401/04 ,  A61K31/506 ,  A61K31/496 ,  C07D401/14 ,  C07D413/14 ,  A61K31/5377 ,  A61P35/02

    CPC分类号： C07D401/14 ,  C07D405/14

    摘要： The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.

    摘要翻译： 本发明涉及下式的化合物，其中取代基R 1，R 2和R 4具有本发明说明书中阐述和解释的含义，制备这些化合物的方法，含有它们的药物组合物，其任选组合的用途 与一种或多种用于治疗对蛋白激酶活性，特别是肿瘤性疾病，特别是白血病的抑制作出反应的疾病的其它药学活性化合物，以及治疗这种疾病的方法。